Curriculum
SILVIA PASQUINI
CURRENT POSITION
Researcher Tenure Track (RTT), academic discipline BIOS-11/A, Pharmacology, Department of Translational Medicine, Unife
QUALIFICATIONS
- 09/10/2013: Bachelor's degree in Biological Sciences, Unife
- 21/10/20215: Master's degree in Biomolecular and Cellular Sciences, Unife
- 25/03/2020: PhD in Molecular Medicine and Pharmacology, Unife
TEACHING ACTIVITY
Teaching activities as part of university training for teaching in the disciplinary scientific sector BIOS-11/A:
- Module of Research Methodology in the Biomedical-Pharmacological Field of the integrated course of Research Methodology at the Master's degree courses in Science of Health Professions Diagnostic Techniques, Nursing and Midwifery Sciences, Unife.
- Teaching of Radio-pharmacology I at the Graduate School of Pharmacology and Clinical Toxicology, Unife.
- Teaching of Pharmaceutical Development at the School of Specialization in Pharmacology and Clinical Toxicology, Unife.
- Teaching of Pharmacoepidemiology at the Graduate School of Pharmacology and Clinical Toxicology, Unife.
- Teaching of Radio-Pharmacology II at the Graduate School of Pharmacology and Clinical Toxicology, Unife.
- Supervision and tutoring of internship students and PhD students at the Laboratory of Cellular and Molecular Pharmacology, Department of Translational Medicine, Unife.
MANAGEMENT ACTIVITIES
- Deputy director of the I-II level master in Methodology of Research and Clinical Trials, Unife.
- Member of the Italian Society of Pharmacology (SIF).
RESEARCH ACTIVITY
- Publications: 42 articles in international scientific journals, H index: 15, citations: 771 (14/01/2025, Scopus). A total of 14 presentations as posters or oral communications at International and National Congresses.
Participation in Research Projects:
- 2015: IGEA SpA - project title: ‘Effect of pulsed electromagnetic field exposure in hypoxia and inflammation’.
- 2016: IGEA SpA - project title: ‘Effect of pulsed electromagnetic field exposure in hypoxia and inflammation induced damage in microglial cells’.
- 2017: IGEA SpA - project title: ‘Signaling pathways involved in the reduction of hypoxia and inflammation induced damage in microglial and neuron-like cells by pulsed electromagnetic field exposure’.
- 2017: Phytoplant Research - project title: ‘Binding studies of phytocannabinoids at the cannabinoid receptors CB1 and CB2’.
- 2018: IGEA SpA - project title: ‘In vitro effects of long-term chronic treatment of pulsed electromagnetic fields on metabolism and cell vitality’.
- 2020-2022: PRIN 2017- National Scientific Coordinator: Prof. Marco Mor. Project title: ‘Exploiting the EndoCannabinoid System to control inflammation and promote neuroprotection and myelin repair (ExECS)’.
- 2021-2023: Project JOCARE ‘Biophysical Stimulation Medical Device for Joint Cartilage Regeneration’ - Project financed by the Ministry of Economic Development (MISE).
- 2021- 2023: FIR Project: ‘Study of cytotoxic and antiproliferative effects of an innovative and selective agent for radiometabolic therapy, 64CuCl2, in cancer cells’.
- 2023-2024: IMMAGINA2A Project - Cancer immunotherapy using A2A inverse agonists - Patent valorisation programmes through the funding of Proof of Concept (PoC) projects of Italian Universities.
Main Research Topics in Preclinical Pharmacology
- Pharmacological characterization of novel G-protein-coupled membrane receptor ligands such as adenosine receptors, cannabinoid receptors and melatonin receptors through the study of drug-receptor interaction and the evaluation of pharmacodynamic parameters such as affinity, potency and efficacy.
- Pharmacological characterization of novel enzyme inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) enzymes, capable of modulating the endocannabinoid system, which can be used as possible anti-inflammatory or neuroprotective agents.
- Study of the expression and functionality of adenosine receptors, assessing the expression levels of messenger RNA of the different receptor subtypes, receptor density and possible alterations of the receptor structure in different pathologies, mainly in inflammatory-based diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, but also in central nervous system diseases such as Parkinson's disease, Alzheimer's disease and cerebral ischaemia.
- Study of the modulation of adenosine receptors by pharmacological treatments with agonists, antagonists or allosteric modulators of adenosine receptors in in vitro models of both central and peripheral pathologies, particularly in pathologies with a significant inflammatory component. In addition to chemical pharmacological treatments, of particular interest is the study of physical stimuli such as pulsed electromagnetic fields for the treatment of diseases of the central nervous system but also of diseases at the joint level and for cartilage regeneration.
